Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1379508 | 0.84 | P2RX7 (0.44) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL3401108 | 0.84 | P2RX7 (0.44) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL11531412 | 0.84 | P2RX7 (0.44) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL27196361 | 0.80 | GSK3B (0.51) | CTNNB1WNT3AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL917137 | 0.79 | CYP1A2 (0.53) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL29508230 | 0.79 | CYP1A2 (0.53) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL5160899 | 0.79 | P2RX7 (0.47) | P2RX7FAAHCTNNB1WNT3ABRD4 | |
| SCHEMBL4865510 | 0.78 | KMT2A (0.46) | NAMPTKMT2AMEN1SMN1; SMN2CDC7 | |
| SCHEMBL13827559 | 0.78 | P2RX7 (0.50) | P2RX7FAAHCTNNB1WNT3ABRD4 | |
| Hydrochloric Acid SCHEMBL27922723 | 0.78 | CYP1A2 (0.51) | P2RX7FAAHCTNNB1WNT3ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781440-B2 | Use of substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1H)one derivatives | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20080269257-A1 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| US-7388005-B2 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-a]pyrimidin-5(1H)one derivatives for neurodegenerative disorders | SANOFI-AVENTIS (FR) | 2008-06-17 | — | — | US | disclosed |
| CN-100391959-C | Pyrimidin-5- (1H) -one derivatives | SANOFI AVENTIS (FR) | 2008-06-04 | — | — | CN | disclosed |
| CN-1827619-A | Pyrimidin-5- (1H) -one derivatives | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | CN | disclosed |
| CN-1247586-C | Substituted 2-pyrimidinyl-6, 7,8, 9-tetrahydropyrimido [1, 2-A ] pyrimidin-4-one and 7-pyrimidinyl-2, 3-dihydroimidazo [1, 2-A ] pyrimidin-5 (1H) one derivatives for the treatment of neurodegenerative diseases | SANOFI AVENTIS SYNTHELABO (FR) | 2006-03-29 | — | — | CN | disclosed |
| EP-1430056-B1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI AVENTIS (FR) | 2005-10-26 | — | — | EP | disclosed |
| US-20040266793-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders | SANOFI (FR) | 2004-12-30 | — | — | US | disclosed |
| CN-1556810-A | Substituted 2-pyrimidinyl-6, 7,8, 9-tetrahydropyrimido [1, 2-A ] pyrimidin-4-one and 7-pyrimidinyl-2, 3-dihydroimidazo [1, 2-A ] pyrimidin-5 (1H) one derivatives for the treatment of neurodegenerative diseases | ����ɳŵ��-����������˾ | 2004-12-22 | — | — | CN | disclosed |
| EP-1430056-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | Sanofi-Aventis (FR) | 2004-06-23 | — | — | EP | disclosed |
| EP-1340760-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003027115-A1 | SUBSTITUTED 2-PYRIMIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-A]PYRIMIDIN-4-ONE AND 7-PYRIMIDINYL-2,3-DIHYDROIMIDAZO[1,2-A]PYRIMIDIN-5(1H)ONE DERIVATIVES FOR NEURODEGENERATIVE DISORDERS | SANOFI-SYNTHELABO (FR) | 2003-04-03 | — | — | WO | disclosed |
| EP-1295884-A1 | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives | SANOFI-SYNTHELABO (FR) | 2003-03-26 | — | — | EP | disclosed |
| US-4144339-A | TREATMENT OF BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1979-03-13 | — | — | US | disclosed |
| US-4138487-A | NEMATOCIDES | RHONE-POULENC INDUSTRIES (FR) | 1979-02-06 | — | — | US | disclosed |
| US-4110450-A | BILHARZIASIS | RHONE-POULENC INDUSTRIES (FR) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269257-A1 | Use of Substituted 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A] Pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-A] Pyrimidin-5(1H)one Derivatives | CDK5, PSEN2, PSEN1 | P2RX7 607/4885FAAH 4774/4885CTNNB1 150/4885 |
| US-20040266793-A1 | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders | CDK5, GSK3A, GSK3B | P2RX7 3461/4885FAAH 4062/4885CTNNB1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.